Listing noticeRegulatory filing
What was reported
On July 31, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1).U.S. Securities and Exchange Commission (EDGAR) · 8-K: FORM 8-K · Jul 31, 2026 · Open the source ↗
What the evidence supports
Humacyte told the SEC (Form 8-K, Item 3.01) that it received or gave a notice concerning its stock exchange listing. The filing gives Jul 31, 2026 as the date of the earliest event reported.
What remains unknown
Whether the company will regain compliance or be delisted; that depends on later events and the exchange's decision.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 3.01 textOn July 31, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1).U.S. Securities and Exchange Commission (EDGAR) · 8-K: FORM 8-K · Jul 31, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
Humacyte reports a notice about its stock exchange listing (Form 8-K, Item 3.01)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.